Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
UBS
US Army
Johnson and Johnson
Merck
Cipla
US Department of Justice
Moodys
McKinsey

Generated: December 10, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DOLOPHINE HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Dolophine Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00149630 Pharmacogenetics of Disulfiram for Cocaine Completed National Institute on Drug Abuse (NIDA) Phase 2 Previous research has shown that disulfiram, a medication sometimes used for treating alcoholism, discourages cocaine use among cocaine addicts who are undergoing methadone treatment. By blocking the enzyme dopamine beta hydroxylase (DBH), disulfiram increases levels of dopamine and produces an unpleasant sense of hyperstimulation and discomfort in cocaine users. This study will evaluate the effectiveness of disulfiram in preventing drug relapse among cocaine and opiate addicts with varying inherited levels of DBH.
NCT00149630 Pharmacogenetics of Disulfiram for Cocaine Completed Yale University Phase 2 Previous research has shown that disulfiram, a medication sometimes used for treating alcoholism, discourages cocaine use among cocaine addicts who are undergoing methadone treatment. By blocking the enzyme dopamine beta hydroxylase (DBH), disulfiram increases levels of dopamine and produces an unpleasant sense of hyperstimulation and discomfort in cocaine users. This study will evaluate the effectiveness of disulfiram in preventing drug relapse among cocaine and opiate addicts with varying inherited levels of DBH.
NCT00149630 Pharmacogenetics of Disulfiram for Cocaine Completed Baylor College of Medicine Phase 2 Previous research has shown that disulfiram, a medication sometimes used for treating alcoholism, discourages cocaine use among cocaine addicts who are undergoing methadone treatment. By blocking the enzyme dopamine beta hydroxylase (DBH), disulfiram increases levels of dopamine and produces an unpleasant sense of hyperstimulation and discomfort in cocaine users. This study will evaluate the effectiveness of disulfiram in preventing drug relapse among cocaine and opiate addicts with varying inherited levels of DBH.
NCT00879996 Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients Completed National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 4 The purpose of this study is to determine if buprenorphine or methadone is better for the treatment of chronic pain among patients who have become addicted to prescription narcotics.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Dolophine Hydrochloride

Condition Name

Condition Name for Dolophine Hydrochloride
Intervention Trials
Laminectomy 1
Postoperative Pain 1
Kyphosis 1
Pain, Postoperative 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Dolophine Hydrochloride
Intervention Trials
Pain, Postoperative 3
Back Pain 1
Syndrome 1
Opioid-Related Disorders 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Dolophine Hydrochloride

Trials by Country

Trials by Country for Dolophine Hydrochloride
Location Trials
United States 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Dolophine Hydrochloride
Location Trials
Illinois 2
New York 2
California 1
Maine 1
Kentucky 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Dolophine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Dolophine Hydrochloride
Clinical Trial Phase Trials
Phase 4 5
Phase 2 1
Phase 1 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Dolophine Hydrochloride
Clinical Trial Phase Trials
Completed 4
Withdrawn 2
Recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Dolophine Hydrochloride

Sponsor Name

Sponsor Name for Dolophine Hydrochloride
Sponsor Trials
State University of New York at Buffalo 2
Northwestern University 2
National Institute on Drug Abuse (NIDA) 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Dolophine Hydrochloride
Sponsor Trials
Other 10
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Deloitte
Healthtrust
Daiichi Sankyo
Harvard Business School
Chubb
Citi
McKinsey
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.